05.31.07
Posted in Uncategorized at 1:00 am by Cancer / Oncology News From Medical News Today
Beginning next week, thousands of Michigan patients will have a new -- virtually pain free -- defense in the fight against cancer. Saint Joseph Mercy Health System (SJMHS) announced today it will begin treating patients with the CyberKnife(R) Robotic Radiosurgery System on Wednesday, June 6th. This advanced radiosurgery system non- invasively treats cancers anywhere in the body, including previously inoperable tumors, with astounding accuracy and with little to no discomfort. [click link for full article]
Permalink
Posted in Uncategorized at 1:00 am by Cancer / Oncology News From Medical News Today
The US Food and Drug Administration (FDA) yesterday approved Wyeth's new drug Torisel (chemical name temsirolimus) for the treatment of renal cell carcinoma, the most common form of advanced kidney cancer.The FDA approval was based on the results of a clinical trial published today in the New England Journal of Medicine. [click link for full article]
Permalink
05.30.07
Posted in Uncategorized at 9:40 pm by Yahoo! Health: Cancer News
The U.S. Food and Drug Administration on Wednesday gave its approval to a new drug called Torisel (temsirolimus) for treating renal cell carcinoma, a type of advanced kidney cancer.
Permalink
Posted in Uncategorized at 9:40 pm by Yahoo! Health: Breast Cancer News
Black women who routinely use hair relaxers can relax: The products will
not increase their risk of breast cancer, a new study finds.
Permalink
Posted in Uncategorized at 9:00 pm by Cancer / Oncology News From Medical News Today
A team led by Dana-Farber Cancer Institute scientists has developed a more human-like mouse model of cancer they say will aid the search for cancer-causing genes and improve the predictive value of laboratory drug testing.Ronald A. DePinho, MD, of Dana-Farber has created mice that form tumors that are more genetically complex and unstable -- and therefore a better stand-in for human cancers -- than those of conventional genetically engineered mouse models of cancer. [click link for full article]
Permalink
Posted in Uncategorized at 1:00 pm by Cancer / Oncology News From Medical News Today
97% of patients with cancer treated with monoclonal antibodies - cetuximab, matuzumab, or panitumumab - that target the epidermal growth factor receptor (EGFR) have some degree of magnesium loss (hypomagnesaemia), according to a study published today in the May issue of The Lancet Oncology. [click link for full article]
Permalink
Posted in Uncategorized at 2:00 am by Cancer / Oncology News From Medical News Today
The European Medicines Agency (EMEA) has been formally notified by Protherics PLC of itsdecision to withdraw the application for a centralised marketing authorisation for the medicinalproduct Voraxaze (glucarpidase) powder for solution for injection 1000 Units. Voraxaze was expected to be used in the adjunctive treatment of patients who are experiencing or atrisk of methotrexate toxicity. [click link for full article]
Permalink
Posted in Uncategorized at 2:00 am by Cancer / Oncology News From Medical News Today
The Honourable Tony Clement, Minister of Health, congratulated the new Chair and the rest of the Board of Directors of the new Canadian Partnership Against Cancer Corporation today, as they held their second Board meeting. "I am very pleased by the calibre of individuals who have agreed to serve on the Board of Directors for the Canadian Partnership Against Cancer Corporation," said Minister Clement, following his meeting with the Board. [click link for full article]
Permalink
Posted in Uncategorized at 1:00 am by Cancer / Oncology News From Medical News Today
A large number of targeted therapeutics entered phase I clinical trials during the past year, and many more, currently in late stage preclinical testing, will soon follow. In addition, of the 92 agents that entered monotherapy clinical trials in 2005, many have advanced to phase II monotherapy and phase I combination trials. [click link for full article]
Permalink
Posted in Uncategorized at 1:00 am by Cancer / Oncology News From Medical News Today
Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that three presentations will be given at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for June 1 - 5, 2007, in Chicago, Illinois. [click link for full article]
Permalink
« Previous entries · Next entries »
